Cardiome Pharma (CRME) Stock Price Up 0.6%
Cardiome Pharma Corp (NASDAQ:CRME) (TSE:COM) rose 0.6% during mid-day trading on Wednesday . The company traded as high as $2.38 and last traded at $1.80. Approximately 369,007 shares traded hands during trading, an increase of 134% from the average daily volume of 157,688 shares. The stock had previously closed at $1.79.
CRME has been the topic of a number of analyst reports. Mackie raised Cardiome Pharma to a “buy” rating in a research report on Friday, December 15th. HC Wainwright set a $10.00 price target on Cardiome Pharma and gave the stock a “buy” rating in a research report on Wednesday. Finally, Canaccord Genuity set a $5.00 price target on Cardiome Pharma and gave the stock a “buy” rating in a research report on Wednesday. One research analyst has rated the stock with a sell rating, one has assigned a hold rating and three have given a buy rating to the company. The company has a consensus rating of “Hold” and an average target price of $5.67.
The company has a debt-to-equity ratio of 1.67, a current ratio of 5.52 and a quick ratio of 4.71. The company has a market cap of $62.00, a P/E ratio of -2.09 and a beta of 0.65.
ILLEGAL ACTIVITY NOTICE: This story was reported by Watch List News and is the property of of Watch List News. If you are reading this story on another domain, it was illegally copied and republished in violation of US & international copyright laws. The original version of this story can be read at https://www.watchlistnews.com/cardiome-pharma-crme-stock-price-up-0-6/1958731.html.
About Cardiome Pharma
Cardiome Pharma Corp. (Cardiome) is a specialty pharmaceutical company. The Company is engaged in the development and commercialization of cardiovascular therapies for heart disease. The Company’s segments are Europe and Rest of World. Cardiome has two marketed, in-hospital, cardiology products, which include BRINAVESS (vernakalant IV), approved in Europe and other territories for the conversion of onset atrial fibrillation (AF) to sinus rhythm in adults, and AGGRASTAT (tirofiban hydrochloride (HCl)), indicated for use in patients with acute coronary syndrome.
Receive News & Ratings for Cardiome Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cardiome Pharma and related companies with MarketBeat.com's FREE daily email newsletter.